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Abstract Autosomal dominant polycystic kidney disease
(ADPKD) is a progressive chronic kidney disease. To date
there are no effective medicines to halt development and
growth of cysts. In the present study, we explored novel
effects of celecoxib (CXB), a COX-2 speciﬁc inhibitor, on
primary cultures of human ADPKD cyst-lining epithelial
cells. Primary cultures of ADPKD cyst-lining epithelial
cells were obtained from ﬁve patients. Effects of CXB were
measured by various assays to detect BrdU incorporation,
apoptosis and proliferation in vitro. Additionally, effects of
CXB on kidney weight, the cyst index, the ﬁbrosis index,
blood urea nitrogen (BUN), serum creatinine (SCr), serum
6-keto-PGF-1a, serum thromboxane-2 (TXB2) and renal
PCNA expression were assessed in Han:SPRD rat, a well-
characterized rodent model of PKD. CXB inhibited pro-
liferation of ADPKD cyst-lining epithelial cells, blocked
the release of VEGF from the cells and induced extensive
apoptosis in a time- and dose-dependent manner. More-
over, CXB up-regulated the cell cycle negative regulator
p21
CIP/WAF1 and the cell cycle positive regulator Cyclin A,
blocked ERK1/2 phosphorylation, induced apoptotic fac-
tors (Bax and caspase-3) and reduced Bcl-2. Furthermore,
CXB inhibited the expression of VEGFR-2 and Raf-1 in
ADPKD cyst-lining epithelial cells. CXB markedly
reduced the cyst index, the ﬁbrosis index, leukocyte inﬁl-
tration, BUN, SCr, serum 6-keto-PGF-1a, TXB2 and renal
PCNA expression in Han:SPRD rat. We demonstrated for
the ﬁrst time that CXB could suppress renal cyst-lining
growth both in vitro and in vivo in Han:SPRD rat. CXB can
inhibit proliferation, suppress cell cycle progression, and
induce apoptosis in ADPKD cyst-lining epithelial cells
through the inhibition of the VEGF/VEGFR-2/Raf-1/
MAPK/ERK signaling pathway.
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Introduction
Celecoxib (CXB), a highly selective cyclooxygenase
(COX-2) inhibitor, is a sulfa non-steroidal anti-inﬂamma-
tory drug (NSAID) used in the treatment of rheumatoid
arthritis, osteoarthritis, acute pain [1], amyotrophic lateral
sclerosis [2], and painful menstruation and menstrual
symptoms. Furthermore, it reduces the number of colon
and rectum polyps in patients with familial adenomatous
polyposis [3]. CXB was reported to signiﬁcantly inhibit the
growth of colon or rectal cancer tumor cells [4, 5], head
and neck cancer cells [6], leukemia cells [7], lung cancer
cells [8] and others. In fact, CXB has recently been clini-
cally evaluated for its antitumor effects [9, 10]. In the
kidney, a signiﬁcant association between maximal COX-2
immunostaining and clinical response was observed in
renal cell carcinoma [11]. However, continuous therapy
with low-dose cyclophosphamide and CXB was reported to
have limited efﬁcacy in treating renal cell carcinoma [12].
Autosomal dominant polycystic kidney disease (ADPKD)
is the most common kidney hereditary disorder that occurs in
1:1,000 individuals and is responsible for 10% of end-stage
renaldisease(ESRD)[13].Itssymptomsmayvaryfromnone
to a variety of problems such as bleeding, pain, urinary
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DOI 10.1007/s11033-012-1611-2infection, kidney stones and kidney failure [14–16]. Geneti-
cally, mutations in the gene on chromosome 16, which codes
fortheproteinpolycystin1,orthePKD2geneonchromosome
4, which codes for the protein polycystin 2, cause ADPKD.
Onlyafewfamilialcasesareunrelatedtoeitherlocus[17].To
date, effective clinical interventions are minimal [18]. It was
reported that COX-2 had high expression in the kidney of an
ADPKDanimalmodel [19],suggestingthat COX-2mightbe
implicated in the pathophysiology of ADPKD, thereby mak-
ing COX-2 an attractive therapeutic target. In fact, it was
recently reported that NS-398, a selective COX-2 inhibitor,
markedly slowed disease progression and attenuated altered
prostanoid production in a rat model [20]. However, the
underlying mechanism remains unclear. More importantly,
theeffectsofCOX-2inhumanADPKDcellsareunknown.In
this study, we report that inhibition of COX-2 with CXB
preventsgrowthofhumanADPKDcyst-liningepithelialcells
by targeting cell cycle and apoptotic pathways, which may
provide new insight for future treatment of ADPKD.
Materials and methods
Patients and cell culture
ADPKD cyst-lining epithelial tissues were obtained from
ﬁve individuals with histologically conﬁrmed ADPKD.
Cells were isolated and cultured as described previously
[21]. Ethical committee approval for tissue collection was
obtained from the Second Military Medical University
Afﬁliated Changzheng Hospital. Informed consent was
obtained from every patient. After nephrectomy, the lesion
tissues were isolated, cut into pieces, and then digested
with collagenase (0.1%) in a 37C incubator for 1 h. AD-
PKD cyst-lining epithelial cells were incubated in a CO2
incubator (37C; 5% CO2 in air) and cultured in Dul-
becco’s modiﬁed eagle’s medium (DMEM) plus 10% fetal
bovine serum (FBS). The third passage of cultured cells in
the logarithmic growth phase was randomly divided into
groups for further treatments.
BrdU cell proliferation assay
A BrdU cell proliferation assay was performed as reported
previously [22]. Cells were seeded into 96-well plates at a
density of 3 9 10
4 cells/well. When the culture reached
80%conﬂuence,serum-free DMEM ? F12(GIBCO, USA)
medium was added. After synchronization for 24 h, CXB
(Pﬁzer, USA) at various concentrations (0, 2.5 9 10
-6,
5 9 10
-6,19 10
-5,29 10
-5,39 10
-5,49 10
-5 and
5 9 10
-5 mol/l) was added to the media. Cells continued to
grow for 24, 48 and 72 h. BrdU-labeled working solution
(10 ll; Roche, Switzerland) was then added to each well
according to the manufacturer’s protocol. Absorbance was
measured at 405 nm to determine the BrdU concentration in
each sample. Anabsorbance measurement at490 nm served
as a control.
Assessment of vascular endothelial growth factor
(VEGF) and PGE2 secretion
Human polycystic kidney cyst-lining epithelial cells were
seeded into three 6-well plates at a density of 5 9
10
4 cells/well. For each plate, six different concentrations
of CXB (0, 1 9 10
-6,59 10
-6,19 10
-5,29 10
-5 and
3 9 10
-5 mol/l) were added. Three plates were cultured
for 12, 24 and 48 h. The supernatant of each well was
collected to detect VEGF and PGE2 absorbance values
(A) using an enzyme-linked immunosorbent assay (ELISA)
kit (Roche, Switzerland) at 450 nm [23].
Assessment of cell cycle and proliferation
Human polycystic kidney cyst-lining epithelial cells were
seeded into three 6-well plates at a density of 4 9
10
4 cells/well. CXB was added at three different concen-
trations (0, 1 9 10
-5,29 10
-5 mol/l). Plates were incu-
bated at 37C for 24, 48 and 72 h. Cells were then
harvested and washed in phosphate buffered saline (PBS)
followed by ethanol ﬁxation. Cells were stained with pro-
pidium iodide (PI) before ﬂow cytometry (Becton–Dick-
inson) analysis as reported previously [24].
RNA isolation and qPCR analysis
Human polycystic kidney cyst-lining epithelial cells were
seededintothree60-mmdishesatadensityof5 9 10
4 cells/
dish. CXB was added to the dishes at three different con-
centrations (0, 1 9 10
-5,2 9 10
-5 mol/l). Cells were
incubated for 24 h and then washed three times in cooled
PBS. Total RNA was extracted with Trizol (Takara, Japan).
The quality of each RNA sample was assessed by electro-
phoresis. RNA was reverse transcribed to complementary
DNA (cDNA) as previously reported [25]. cDNA was syn-
thesized in 20 ll of reaction mixture from 2 lg of RNA.
Quantitative(orreal-time,q)PCR(AppliedBiosystems)was
completed using SYBR Green I (BioRad, USA). The
housekeeping gene GAPDH was used as an internal control
[26] to estimate relative quantity of mRNA expression and
correct for differences in sample volumes Table 1.
Apoptosis assays
Apoptosis in ADPKD cells was evaluated by terminal
deoxynucleotide transferase-mediated dUTP nick end-
labeling (TUNEL) staining and Annexin V ? PI staining
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123analysis. TUNEL was used to detect the cellular apoptosis
rate as reported previously [27]. Procedures were carried
out according to the kit instructions (Roche, Switzerland).
TUNEL reaction solution was substituted with TdT-free
solution for a negative control. Sections were pretreated
10 min with DNase and visualized by diaminobenzidine
(DAB) staining. Positive nuclei were identiﬁed by brown
color. The calculation method for determining the number
of apoptotic cells was as follows: 10 ﬁelds of vision under
microscopy (9400) were randomly selected and the
apoptosis rate (%) = (the number of positive cells/the total
number of ADPKD cyst-lining epithelial cells) 9 100%.
For Annexin V/PI staining analysis, the Alexa Fluor 488
labeled-Annexin V and PI assay (Invitrogen, Carlsbad, CA,
USA) were used according to the manufacturer’s instruc-
tion. A BD FACScalibur ﬂow cytometer was used.
Western blot analysis
Western blot analysis was performed as described previ-
ously [28, 29]. Human polycystic kidney cyst-lining epi-
thelial cells were seeded into ﬁve 60 mm culture dishes at a
density of 5 9 10
4 cells/dish. CXB (2 9 10
-5 mol/l) was
added to each dish and incubated for 0, 12, 24, 36 and 48 h.
In an additional experiment, cells were stimulated by
VEGF (40 ng/ml) for 24 h and then treated with CXB
(20 lM) and a Raf/VEGFR2 inhibitor (NVP-AAL881,
2 lM) for 48 h. Cells were then lysed and total protein was
extracted. Membrane protein was extracted using the
Membrane and Cytoplasmic Protein Extraction Kit (San-
gon, China, catalogue: BSP005). Protein concentration was
measured with a BCA protein assay kit (Pierce, USA).
Protein (40 lg) from each dish was loaded for polyacryl-
amide gel electrophoresis (SDS-PAGE, resolving gel con-
centration was 12%) and transferred to nitrocellulose
membranes at 100 V for 2 h. The membrane was blocked
by treatment with 5% nonfat milk for 1 h at room tem-
perature and was probed at 4C overnight with 11 different
primary antibodies: mouse anti-human PCNA (1:200,
Santa Cruz), mouse anti-human ERK1/2 (1:2,000, Cell
Signaling Technology), rabbit anti-human phospho-ERK1/
2 (1:1,000, Cell Signaling Technology), mouse anti-human
p21
CIP/WAF1 (1:200, Santa Cruz), mouse anti-human Cyclin
A (1:1,000), mouse anti-human Bax (1:100, Santa Cruz),
mouse anti-human Bcl-2 (1:100, Santa Cruz), mouse anti-
human caspase-3 (1:800, Santa Cruz), rabbit anti-human
VEGFR-2 (1:800, Santa Cruz), rabbit anti-human Raf-1
(1:800, Santa Cruz) and mouse anti-human GAPDH
(Sigma). After washing with PBS, the membrane was
incubated with the corresponding HRP-labeled secondary
antibody for 2 h at room temperature. The membrane was
washed in PBS again and then transferred to ECL working
solution (Pierce). The ﬁlm was exposed and scanned. The
optical density of protein bands was quantiﬁed and GAP-
DH protein served as the internal control [30].
In vivo study in heterozygous (Cy/?) Han:SPRD rat
The (Cy/?) Han:SPRD rat is a well-established animal
model for PKD. Three-week-old (Cy/?) male rats were
randomly divided into three groups: a control group, a low-
dose CXB (30 mg/kg/day) group and a high-dose CXB
(100 mg/kg/day) group. The control group received a nor-
mal diet while the latter two groups received a normal diet
plus CXB. Blood was obtained from the vena orbitalis
posterior at 4, 6, 8, 10, 12 and 16 weeks of treatment. Blood
urea nitrogen (BUN) and serum creatinine (SCr) were
determined with an automatic biochemistry analyzer (Hi-
tach 7080, Tokyo, Japan). Serum 6-keto-PGF-1a and serum
thromboxane-2 (TXB2) were measured using commercial
ELISA kits (Cayman,USA). After 16 weeks, the rats were
anesthetized with sodium pentobarbital (40 mg/kg) and the
kidneys were removed. Fresh kidneys were isolated and cut
into three parts. One portion of the tissues was ﬁxed in 10%
formalin and subjected to hematoxylin–eosin (HE) staining,
periodic acid-Schiff (PAS) staining and Masson staining as
described previously [31] to evaluate the cyst index, the
ﬁbrosis index and leukocyte inﬁltration. A second portion of
the tissues was used to perform immunohistochemistry as
described previously [32]. The last portion of the tissues
was homogenized and then subjected to immunoblot anal-
ysis of phospho-ERK and Raf-1 expression.
Statistical analysis
All data were expressed as means ± SD. Paired compari-
son was performed using one-way analysis of variance
(ANOVA) or two-way ANOVA followed by the SNK t test
(SPSS version 11, Chicago, IL, USA). P\0.05 was con-
sidered statistically signiﬁcant.
Results
CXB inhibits ADPDK cell proliferation
As shown in Fig. 1a, different concentrations of CXB
ranging from 1 to 50 lM signiﬁcantly inhibited ADPKD
cell proliferation in a dose-dependent manner. No signiﬁ-
cant differences were observed between responses to 20
and 50 lM of CXB, suggesting 20 lM might be the
maximum effective dose of CXB in ADPDK cells. More-
over, we evaluated the effect of CXB on PCNA mRNA
expression, a marker for cell proliferation (Fig. 1b). PCNA
expression was signiﬁcantly reduced in ADPKD cyst-
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123lining epithelial cells when treated with 10 lM CXB, and
was further decreased when treated with 20 lM CXB.
CXB inhibits VEGF and PGE2 secretion
CXB signiﬁcantly inhibited VEGF release from cultured
ADPKD cyst-lining epithelial cells. As shown in Fig. 2a,
20 lM CXB resulted in a maximum inhibitory effect at
48 h (P\0.05). The inhibitory effect occurred in a time-
and dose-dependent manner. In contrast, the inhibitory
effect of CXB on PGE2 secretion was neither time- nor
dose-dependent (Fig. 2b). CXB at 20 lM reached a max-
imum inhibitory effect at 12 h (P\0.05).
CXB induces cell cycle arrest
As shown in Fig. 3,a2 0lM CXB treatment for 24 h
induced cell cycle arrest at the S phase (Fig. 3a, P\0.05),
while the number of G2/M phase cells decreased (Fig. 3a,
P\0.05). This effect on cell cycle was less in cells
incubated with 10 lM CXB (Fig. 3a). When the concen-
tration of CXB and exposure time increased, the effects of
cell cycle arrest became more apparent (48 h, Fig. 3b;
72 h, Fig. 3c).
CXB treatment induces apoptosis in ADPKD cyst-
lining epithelial cells
As shown in Fig. 4a, there were signiﬁcantly more cells
stained with DAB in apoptotic ADPKD cyst-lining epi-
thelial cells (red arrow, 28.5 ± 1.6% vs. 2.8 ± 0.2%,
P\0.01) than in control cells. Under the microscope,
typical apoptotic phenomena (brown nucleus, nuclear
condensation, chromatin margination, condensation and
scattered brown apoptotic bodies) were identiﬁed in CXB-
treated cells. Apoptotic rates signiﬁcantly differed between
Fig. 1 Cell proliferation in
ADPKD cells. a ADPKD cyst-
lining epithelial cell
proliferation was determined by
a BrdU assay. b PCNA mRNA
expression was determined
using real-time PCR.
*P\0.05, **P\0.01 vs.
control; n = 8
Fig. 2 Effects of CXB on
secretion of VEGF and PGE2
from ADPKD cells. Levels of
VEGF (a) and PGE2 (b)i n
media were determined by
ELISA. *P\0.05, **P\0.01
vs. control; n = 8
Fig. 3 Effects of CXB on cell cycle distribution of ADPKD cells. Cell cycle status of ADPKD cells was determined using PI staining and ﬂow
cytometry. Cells were treated with CXB for 24 h (a), 48 h (b) and 72 h (c). *P\0.05, **P\0.01 vs. control; n = 8
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123treatment groups. As shown in Fig. 4b, Annexin V ? PI
staining showed that CXB (5, 10 and 20 lM) induced
marked increases in the number of apoptotic cells in a
time- and dose-dependent manner. Increases in apoptotic
cells were also noted with serum starvation (positive con-
trol). Incubation with 20 lM CXB for 48 h induced max-
imal apoptosis (53.8%). Chromatin aggregation (blue
arrows), apoptotic bodies (green arrow) and naked nuclei
(yellow arrow) were observed by electron microscopy in
cells treated with 20 lM CXB for 24 h (Fig. 4c).
Effects of CXB on mRNA expression of caspase-3, Bax
and Bcl-2
After 24 h of CXB (20 lM) treatment, caspase-3 mRNA
expression did not change (Fig. 5a). However, there was
signiﬁcant up-regulation of the apoptotic gene Bax
(Fig. 5c) and down-regulation of the anti-apoptotic gene
Bcl-2 (Fig. 5b), which resulted in a decrease in the Bcl-2/
Bax ratio (Fig. 5d, P\0.05). After 48 h of treatment, the
mRNA level of caspase-3 was markedly increased
(Fig. 5a) while the changes in Bax and Bcl-2 remained the
same as at the earlier time point.
Effects of CXB on protein expression of ERK1/2
signaling pathway and other apoptosis-related proteins
As shown in Fig. 6a, CXB (20 lM) suppressed the phos-
phorylation of ERK1/2 in a time-dependent manner as
comparedto that in the serum-free control group, while total
ERK1/2proteinexhibitednosigniﬁcantdifferencesbetween
treatmentgroupsoracrosstreatmenttimes.Similarly,PCNA
protein expression was also decreased (Table 1). As shown
inFig. 6b,CXBincreasedtheexpressionofp21
CIP/WAF1and
Bax,whereasCXBdecreasedtheexpressionofCyclinAand
Bcl-2 in a time-dependent manner. Total caspase-3
Fig. 4 Induction of apoptosis in ADPKD cells by CXB. Apoptosis
assays showing CXB induces ADPKD cell apoptosis. a Apoptosis
was evaluated by TUNEL staining. The brown nuclear area indicates
TUNEL-positive cells (red arrows). b Apoptosis was evaluated by
Annexin V ? PI staining with a ﬂow cytometer. c Apoptosis was
evaluated by electron microscopy. (Color ﬁgure online)
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123(precursor, 34 kDa) expression was enhanced after 24 h of
treatment, while the expression of cleaved caspase-3
(17 kDa) was observed only at the 12 h time point.
Effects of CXB on VEGF-related signaling pathway in
vitro
As shown in Fig. 7a, b, VEGF treatment stimulated
VEGFR-2 and Raf-1 expression. Both CXB (20 lM) and
the VEGFR-2/Raf-1 signaling pathway inhibitor NVP-
AAL881 suppressed the up-regulation of VEGFR-2 and
Raf-1.
Effects of CXB on VEGF-Raf-1-ERK1/2 signaling
pathway in (Cy/?) Han:SPRD rat
As shown in Fig. 8a, b, diets supplemented with either of
the two doses of CXB (30 and 100 mg/kg) suppressed the
expression of phospho-ERK1/2 and Raf-1 in Han:SPRD
rat.
Fig. 5 Gene expression of
apoptosis regulatory proteins.
Effects of CXB (20 lM) on
mRNA expression of caspase-3
(a), Bax (b), Bcl-2 (c), and the
Bcl-2/Bax ratio (d). *P\0.05
vs. control. n = 8. GAPDH was
used as a loading control
Fig. 6 Protein expression of
cell cycle and apoptosis
regulatory proteins. Effects of
CXB (20 lM) on ERK1/2
signaling pathway
phosphorylation (a), PCNA
expression (a), Bax/Bcl-2
expression (b), caspase-3
cleavage (b), Cyclin A
expression (b) and p21
CIP/WAF1
expression (b). GAPDH was
used as a loading control.
*P\0.05 vs. control; n = 8.
GAPDH served as a loading
control
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123Effects of CXB on kidney weight and serum parameters
in Han:SPRD rat
As shown in Table 2, diets supplemented with either of the
two doses of CXB (30 and 100 mg/kg) attenuated the
increase in kidney weight in Han:SPRD rat. Moreover,
both doses of CXB (30 and 100 mg/kg) signiﬁcantly
decreased the levels of serum 6-keto-PGF-1a and serum
TXB2 in Han:SPRD rat (Table 3). We also measured the
BUN and SCr levels. As shown in Fig. 9, the BUN and SCr
levels steadily increased in Han:SPRD rat, and these effects
were attenuated by both doses of CXB.
Effects of CXB on kidney morphology and expression
of PCNA in Han:SPRD rat
We applied three staining methods (HE, PAS and Masson
staining, Fig. 10a) to study kidney morphology and cal-
culate the cyst index, the ﬁbrosis index and leukocyte
inﬁltration. Both doses of CXB successfully decreased the
cyst index, the ﬁbrosis index and leukocyte inﬁltration
(Fig. 10b). Finally, CXB markedly inhibited expression of
PCNA (a marker of cellular proliferation) and COX-2 in
(Cy/?) Han:SPRD rat (Fig. 11a, b).
Discussion
In the present study, we showed that CXB suppressed the
proliferation of human ADPKD cyst-lining epithelial cells
by targeting cell cycle and apoptosis pathways in a time-
and dose-dependant manner. This is the ﬁrst report sug-
gesting an anti-growth effect of CXB in human ADPKD
cyst-lining epithelial cells. Although it is the fourth leading
cause of ESRD, there are still no effective therapeutic
interventions for treatment of ADPKD, with the exception
of gene replacement therapy. Thus, we provide additional
evidence for the application of COX-2 inhibitors in the
treatment for ADPKD.
Raz et al. [33] speculated that COX-2 inhibitors func-
tioned as anti-cancer agents primarily through two mech-
anisms: a COX-dependent pathway by inhibiting the COX
enzyme (primarily COX-2), and a COX-2 independent
pathway that induces blockage of cell growth at different
stages of reproduction and causes apoptosis. According to
our results, growth inhibition of human ADPKD cyst-lining
epithelial cells induced by CXB may be due to its pro-
apoptotic and cell cycle arrest properties. Several previous
reports have indicated that CXB can induce apoptosis in
various tumor cells [34, 35]. Using the TUNEL method,
Annexin V ? PI staining and electron microscopy, we
observe that CXB indeed induces apoptosis of ADPKD
cyst-lining epithelial cells.
Moreover, we studied the signals underlying the pro-
apoptotic ability of CXB. We found that CXB could inhibit
the release of VEGF from ADPKD cyst-lining epithelial
cells in a time- and dose-dependant manner. Additionally,
CXB also inhibited secretion of PGE2, but in a time- and
Table 1 Primer sets for qRT-PCR
Primer
name
Sequence Length
(bp)
PCNA F: 50-TCATTACACTAAGGGCCGAAG-30 170
R: 50-TTCACCAGAAGGCATCTTTACT-30
Bax F: 50-GCAAACTGGTGCTCAAGG-30 192
R: 50-CGCCACAAAGATGGTCAC-30
Bcl-2 F: 50-GCCTTCTTTGAGTTCGGTG-30 207
R: 50-CAGAGACAGCCAGGAGAAATC-30
Caspase 3 F: 50-CAGAACTGGACTGTGGCATTG-30 192
R: 50-GCTTGTCGGCATACTGTTTCA-30
GAPDH F: 50-GGT ATC GTG GAA GGA CTC ATG
AC-30
188
R: 50-ATG CCA GTG AGC TTC CCG TTC
AGC-30
Fig. 7 Effects of CXB (20 lM) on VEGF-related signaling proteins
under VEGF stimulation in vitro. Cells were pre-treated with VEGF
(40 ng/ml) for 24 h and then incubated with CXB (20 lM) or NVP-
AAL881 (2 lM) for 48 h. a Representative images of immunoblotting
of VEGFR-2 and Raf-1. b Quantitative analysis of protein expression
of VEGFR-2 and Raf-1. *P\0.05 vs. control;
#P\0.05 vs. VEGF
stimulation; n = 8. GAPDH served as a loading control
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123Fig. 8 Protein expression of phospho-ERK1/2 and Raf-1 in vivo.
Effects of low-dose (30 mg/kg) and high-dose (100 mg/kg) CXB on
phospho-ERK1/2 and Raf-1 in heterozygous (Cy/?) Han:SPRD rat.
a Representative images of immunoblotting of phospho-ERK1/2 and
Raf-1. b Quantitative analysis of protein expression of phospho-
ERK1/2 and Raf-1. *P\0.05 vs. control; **P\0.01 vs. control;
n = 6 per group. GAPDH served as a loading control
Table 2 Characteristics of (Cy/?) Han:SPRD rat after 16 weeks of treatment
Group Body weight (g) Right kidney weight (g) Left kidney weight (g) Kidney weight/body weight (%)
Control 434 ± 33 2.89 ± 0.91 2.87 ± 0.71 1.33 ± 0.48
Low-dose CXB 416 ± 18 2.26 ± 0.53* 2.34 ± 0.34* 1.11 ± 0.49*
High-dose CXB 401 ± 32* 2.28 ± 0.25* 2.33 ± 0.54* 1.14 ± 0.25*
* P\0.05 vs. control
Table 3 Characteristics of (Cy/?) Han:SPRD rat after 16 weeks of treatment
Group Serum 6-keto-PGF-1a (pg/ml) Serum TXB2 (pg/ml)
12 weeks 16 weeks 12 weeks 16 weeks
Control 1830 ± 807 2790 ± 830 139 ± 14 249 ± 94
Low-dose CXB 1380 ± 758* 1830 ± 233* 128 ± 6* 157 ± 9**
High-dose CXB 1310 ± 455* 1150 ± 106* 125 ± 7* 158 ± 10**
*P\0.05 vs. control, **P\0.01
Fig. 9 Effects of CXB on BUN and SCr levels in Han:SPRD rats. Effects of low-dose (30 mg/kg) and high-dose (100 mg/kg) CXB on BUN
(a) and SCr (b) levels in Han:SPRD rat. **P\0.01 vs. control; n = 6 per group
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123dose-independent manner. It is well known that VEGF is
important for the regeneration of ADPKD cyst-lining epi-
thelial cells, the secretion of cystic ﬂuid, hyperplasia of
extracellular matrix, and the growth of new blood vessels
[36]. VEGF can bind to VEGFR-2 and activate Ras,
thereby further activating Raf-1. Raf-1 can then stimulate
MAPK signaling cascades [37]. In pancreatic cancer, Ras/
Raf-1/MAPK signaling is required for mediating growth
factor-induced (such as epidermal growth factor) onco-
genic effects. Activation of this pathway is associated with
tumor progression (proliferation) and invasiveness (cell
migration) [38–40].
We found that VEGF secreted by cultured ADPKD cyst-
lining epithelial cells bound to VEGFR-2 and directly
activated the Ras/Raf-1/MAPK pathway to induce abnor-
mal proliferation. CXB successfully blocked this cascade
and inhibited proliferation of ADPKD cyst-lining epithelial
cells both in vitro and in vivo in Han:SPRD rat. There are
three parallel MAPK signaling cascades, the ERK, JNK
and p38 MAPK pathways. It is well known that inactiva-
tion of both the JNK and ERK pathway inhibits cell pro-
liferation, while the ERK and p38 MAPK pathways both
regulate the cell cycle. ERK1/2 is an important regulator of
apoptosis in tumor cells and Bcl-2/Bax is a downstream
component in the ERK1/2 signal transduction pathway
[41]. Under normal circumstances, caspase-3 is an inactive
pro-enzyme in the cytoplasm. Only when apoptosis is
activated is caspase-3 transformed to the active form [42].
In the CXB treatment group, the ratio of Bcl-2/Bax and the
amount of phospho-ERK1/2 were decreased in time-
dependent manners, suggesting that CXB might increased
the sensitivity of ADPKD cyst-lining epithelial cells to
apoptotic stimuli. However, regarding whether CXB
coordinates the three downstream pathways to inhibit cell
Fig. 10 a Representative
images of HE, PAS and Masson
staining of kidneys from
Han:SPRD rat treated with
vehicle, low-dose (30 mg/kg)
and high-dose (100 mg/kg)
CXB. b Quantitative analysis of
cyst index, ﬁbrosis index and
leukocyte inﬁltration.
*P\0.05 vs. control;
**P\0.01 vs. control; n = 6
per group
Fig. 11 a Representative images of immunohistochemistry of PCNA
(red) and COX-2 (green) in Han:SPRD rat treated with vehicle, low-
dose (30 mg/kg) and high-dose (100 mg/kg) CXB. b Quantitative
analysisofPCNAandCOX-2expressioninHan:SPRDrattreatedwith
vehicle, low-dose (30 mg/kg) and high-dose (100 mg/kg) CXB.
*P\0.05vs.control; **P\0.01vs. control;n = 6 pergroup.(Color
ﬁgure online)
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123proliferation, induce apoptosis and regulate cell cycle
remains unclear and warrants further investigation.
CXB-induced cell cycle arrest, in particular the marked
increase in S phase arrest in ADPKD cells, was an important
ﬁnding in this study. This suggests that the ADPKD cyst-
lining epithelial cells were blocked before G2/M phase,
resulting in an accumulation of cells at the S phase. The
proportion of cells in the S phase indicates the proportion of
cells in a proliferative stage because cycle status is not only
directly related to cell proliferation, but also to cell differ-
entiation and apoptosis. The G1/S check point is crucial for
cell proliferation as it controls the passage of eukaryotic
cells from the ﬁrst ‘gap’ phase (G1) into the DNA synthesis
phase (S), which involves interaction between the positive
regulator CDK2-Cyclin A (also as a G1/S checkpoint reg-
ulator) and the negative regulator p21
CIP/WAF1 [37]. In the
present study, protein expression of p21
CIP/WAF1 in the
ADPKD cells was increased whereas that of the positive
regulator Cyclin A was decreased after CXB treatment,
further indicating that CXB might have inhibited the pro-
liferation of ADPKD cells by targeting the cell cycle.
Finally, we demonstrated the efﬁcacy of CXB in (Cy/?)
Han:SPRD rat, a frequently used animal model of PKD.
CXB remarkably decreased the increases in kidney weight,
serum 6-keto-PGF-1a, serum TXB2, BUN, SCr, the cyst
index, the ﬁbrosis index, leukocyte inﬁltration and PCNA
expression. All these in vivo data clearly showed the potent
and critically beneﬁcial effects of CXB on ADPKD.
Notably, everolimus decreased kidney growth whereas
renal function declined in human ADPKD, suggesting that
possible therapeutic compounds can cause kidney injury
and halt kidney growth. Whether CXB can induce renal
injury needs further investigation in the future.
In summary, our in vitro and in vivo ﬁndings provide the
ﬁrst direct evidence that CXB suppresses renal cyst-lining
growth in ADPKD. Potential mechanisms of action may
include induction of cell cycle arrest and apoptosis, which
are achieved by the blockade of binding between VEGF
and VEGFR-2, and subsequent Raf-1/ERK signaling.
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